Science and Research

First-line immune checkpoint blockade for advanced non-small-cell lung cancer: Travelling at the speed of light

The development of PD-1, PD-L1 and CTLA-4 immune checkpoint inhibitors (CPI) has revolutionised the treatment of advanced non-small cell lung cancer (NSCLC). The potential of immunotherapy (IO) to induce durable responses for a subset of patients represents a therapeutic milestone. After the approval of front-line single agent pembrolizumab, IO-based combinations are rapidly entering clinical practice resulting in a fast change of treatment algorithms for advanced NSCLC. We hereby summarize the recent first-line phase 3 trials evaluating PD-(L)1 blockade plus chemotherapy (ChT) and PD-1 plus CTLA-4 CPI for advanced NSCLC and provide potential treatment recommendations.

  • Ackermann, C. J.
  • Reck, M.
  • Paz-Ares, L.
  • Barlesi, F.
  • Califano, R.


  • *Advanced
  • *ctla-4
  • *Checkpoint inhibitors
  • *Chemotherapy
  • *First-line
  • *Immuno-Oncology
  • *Immunotherapy
  • *nsclc
  • *Non-Small-Cell Lung Cancer
  • *pd-1
  • *pd-l1
Publication details
DOI: 10.1016/j.lungcan.2019.06.007
Journal: Lung Cancer
Pages: 245-253 
Work Type: Original
Location: ARCN
Disease Area: LC
Partner / Member: Ghd
Access-Number: 31319988
See publication on PubMed

DZL Engagements